Business Context and Reporting Period
This Form 6-K filing covers the month of July 2007 for Prana Biotechnology Limited (ASX:PBT), an Australian biotechnology company. The filing serves as a Final Director's Interest Notice pursuant to ASX Listing Rule 3.19A.3 and Section 205G of the Corporations Act. The document discloses the securities holdings of Colin Masters, who ceased to be a director on July 2, 2007.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director shareholdings and does not contain financial performance data.
Material Changes
The primary material change disclosed is the cessation of Colin Masters as a director on July 2, 2007. The filing details his final relevant interests in the company's securities as of that date, which include:
- Registered Shares: 166,666 ordinary shares.
- Options: 1,000,000 unlisted options exercisable at AUD$0.80 (expiring July 31, 2009) and 1,000,000 unlisted options exercisable at AUD$1.00 (expiring June 30, 2010).
- Family Interests: The director holds relevant interests in 18,000 ordinary shares held by family members (Kate Masters, Seth Masters, and Helen Masters).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the disclosure of director interests.
Investor Verification Points
- Verify the total number of options held by the former director (2,000,000) and their respective exercise prices and expiration dates.
- Confirm the exact date Colin Masters ceased to be a director (July 2, 2007) to assess the timing of the disclosure.
- Review the breakdown of shares held by family members to understand the full scope of the director's relevant interests.